A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Ipilimumab (Primary) ; Sargramostim
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Apr 2015 Planned End Date changed from 1 Feb 2013 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 31 May 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 15 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov. (Parent trial: NCT01134614).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History